2012 Fiscal Year Final Research Report
The impact of activated PI3K signal on pancreatic cancer
Project/Area Number |
22590756
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | The University of Tokyo |
Principal Investigator |
SASAHIRA Naoki 東京大学, 医学部附属病院, 助教 (30401102)
|
Co-Investigator(Kenkyū-buntansha) |
TADA Minoru 東京大学, 医学部附属病院, 講師 (80302719)
IJICHI Hideaki 東京大学, 医学部附属病院, 助教 (70463841)
ASAOKA Yoshinari 東京大学, 医学部附属病院, 助教 (90431858)
|
Co-Investigator(Renkei-kenkyūsha) |
IKENOUE Tsuneo 東京大学, 医科学研究所, 准教授 (80396712)
|
Project Period (FY) |
2010 – 2012
|
Keywords | 膵癌 / マウスモデル / 薬剤耐性 / 遺伝子異常 |
Research Abstract |
We generated pancreatic cancer mouse model by inducing pancreas-specific expression of activated Kras and deletion of Pten. All the mice died from pancreas tumor in six weeks. We analyzed the effect of mTOR inhibitor, rapamycin, on pancreatic cancer cell lines with PTEN deletion or AKT2 amplification. Rapamycin had no anti-tumor effect using as a single agent or combination with gemcitabine. We discovered that low glucose medium predisposed these cells to apoptosis and rapamycin prevented this phenomenon. The result suggested that, under some conditions, mTOR inhibition could not exert anti-tumor effect even on PTEN-PI3K-AKT activated cancer.交付決定額(
|
Research Products
(12 results)
-
[Journal Article] Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.2012
Author(s)
Mohri D, Asaoka Y, Ijichi H, Miyabayashi K, Kudo Y, Seto M, Ohta M, Tada M, Tanaka Y, Ikenoue T, Tateishi K, IsayamaH, Kanai F, Fukushima N, Tada M, Kawabe T, Omata M, Koike K.J
-
Journal Title
Gastroenterol
Volume: 47(2)
Pages: 203-13
DOI
-
[Journal Article] Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1.2012
Author(s)
Nakai Y, Isayama H, Ijichi H, Sasaki T, Kogure H, Yagioka H, Miyabayashi K, Mizuno S, Yamamoto K, Mouri D, Kawakubo K, Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K.
-
Journal Title
Cancer Sci
Volume: 103(8)
Pages: 1489-92
DOI
Peer Reviewed
-
[Journal Article] Comorbidity, not age, is prognostic inpatients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy.2011
Author(s)
Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Kogure H, Yagioka H, Yashima Y, Togawa O, Arizumi T, Matsubara S, Hirano K, Tada M, Omata M, Koike K.
-
Journal Title
Crit Rev Oncol Hematol
Volume: 78(3)
Pages: 252-9
DOI
Peer Reviewed
-
[Journal Article] Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas.2011
Author(s)
Kawakubo K, Tada M, Isayama H, Sasahira N, Nakai Y, Yamamoto K, Kogure H, Sasaki T, Hirano K, Ijichi H, Tateishi K, Yoshida H, Koike K.
-
Journal Title
Gut
Volume: 60(9)
Pages: 1249-53
DOI
Peer Reviewed
-
[Journal Article] Specific increase in serum autotaxin activity in patients with pancreatic cancer2011
Author(s)
Nakai Y, Ikeda H, Nakamura K, Kume Y, Fujishiro M, Sasahira N, Hirano K, Isayama H, Tada M, Kawabe T, Komatsu Y, Omata M, Aoki J, Koike K, Yatomi Y.
-
Journal Title
Clin Biochem
Volume: 44(8-9)
Pages: 576-81
DOI
Peer Reviewed
-
[Journal Article] Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.2011
Author(s)
Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Arizumi T,Togawa O, Ito Y, Matsubara S, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K.
-
Journal Title
Oncology
Volume: 80(1-2)
Pages: 97-101
DOI
Peer Reviewed
-
[Journal Article] Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.2011
Author(s)
Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL.J Clin
-
Journal Title
Invest
Volume: 121(10)
Pages: 4106-17
DOI
Peer Reviewed
-
[Journal Article] Impact of S-1 in patients withgemcitabine-refractory pancreatic cancerin Japan2010
Author(s)
Nakai Y, Isayama H, Sasaki T,Sasahira N, Kogure H, Hirano K, Tsujino T,Ijichi H, Tateishi K, Tada M, Omata M,Koike K.
-
Journal Title
Jpn J Clin Oncol
Volume: 40(8)
Pages: 774-80
DOI
Peer Reviewed
-
[Journal Article] Impact of S-1 on the survival of patientswith advanced pancreatic cancer2010
Author(s)
Nakai Y,Isayama H, Sasaki T, Sasahira N, Ito Y,Kogure H, Togawa O, Matsubara S,Arizumi T, Yagioka H, Yashima Y,Kawakubo K, Mizuno S, Yamamoto K,Hirano K, Tsujino T, Ijichi H, Tateishi K,Toda N, Tada M, Omata M, Koike K.
-
Journal Title
Pancreas
Volume: 39(7)
Pages: 989-93
DOI
Peer Reviewed
-
[Journal Article] A genetic polymorphism of CYP2C19 is associated with susceptibility to biliarytract cancer2010
Author(s)
Isomura Y, Yamaji Y, OhtaM, Seto M, Asaoka Y, Tanaka Y, Sasaki T,Nakai Y, Sasahira N, Isayama H, Tada M,Yoshida H, Kawabe T, Omata M, Koike K.
-
Journal Title
J Gastroenterol
Volume: 45(10)
Pages: 1045-52
DOI
Peer Reviewed
-
-